Laurie Sehn, MD from the BC Cancer Agency, Vancouver, Canada and Andrew Zelenetz, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY come together to review the very interesting session on ‘novel lymphoma targets/agents’, which sparked a lot of debate at the 2017 International Workshop on Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. During this session, the results from the GALLIUM study (NCT01332968) were discussed, in which rituximab and obinutuzumab were compared head-to-head in non-Hodgkin lymphoma with the endpoint of progression-free survival being met. Dr Sehn and Dr Zelenetz discuss weighing up toxicity profiles of novel agents and thinking about how best to use them in combination. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.